A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 501-506

  Heresco Levy, Uriel ^a,b   Gelfin, Genia ^a,b   Bloch, Boaz ^c,d   Levin, Raz ^a   Edelman, Shani ^a   Javitt, Daniel C ^e   Kremer, Ilana ^c,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

d cycloserine; depression; NMDAR; treatment

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOSERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ADD ON THERAPY; ADULT; AGED; AMINO ACID BLOOD LEVEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HEARING DISORDER; HUMAN; MAJOR DEPRESSION; MALE; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SEIZURE; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREMOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOSERINE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84874654554     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000910     Document Type: Article

References (25)

1. Beck AT, Steer RA, Brown GK (1996). BDI-II Manual. San Antonio, USA: The Psychological Corporation, Harcourt Brace & Company.
2. Boyer PA, Skolnick P, Fossom LH (1998). Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain : A quantitative in situ hybridization study. Journal of Molecular Neuroscience 10, 219-233. (Pubitemid 28427889)
3. Crane GE (1959). Cycloserine as an anti-depressant agent. American Journal of Psychiatry 115, 1025-1029.
4. Crane GE (1961). The psychotropic effects of cycloserine : A new use for an antibiotic. Comprehensive Psychiatry 2, 51-59.
5. Entsuah AR, Huang H, Thase ME (2001). Response and remission rates in different sub-populations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Journal of Clinical Psychiatry 62, 869-877. (Pubitemid 33131173)
6. Frank E, Prien RF, Jarrett RB, Keller MB (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Archives of General Psychiatry 48, 851-855.
7. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication No. 76-338.
8. Washington, DC: Superintendent of Documents, US Government Printing Office. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 175, 17-22.
9. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
10. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, et al. (2006). Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. Journal of Affective Disorders 93, 239-243. (Pubitemid 43816064)
11. Ji Y, Hebbring S, Zhu H, Jenkins GD (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics 89, 97-104.
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, et al. (1987). The UKU Side Effect Rating Scale : A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica (Suppl.) 334, 1-100. (Pubitemid 17115352)
13. Neeman G, Blanaru M, Bloch B, Kremer I, et al. (2005). Relation of plasma glycine, serine and homocysteine levels to schizophrenia symptoms and medication type. American Journal of Psychiatry 162, 1738-1740. (Pubitemid 41318246)
14. Norberg MM, Krystal JH, Tolin DF (2008). A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 63, 1118-1126.
15. Preskorn SH, Baker B, Kolluri S, Menniti FS, et al. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selection N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631-637.
16. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, et al. (2004). Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 61, 705-713. (Pubitemid 38890805)
17. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426-437. (Pubitemid 351619114)
18. Shleper M, Kartvelishvily E, Wolosker H (2005). D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. Journal of Neuroscience 25, 9413-9417. (Pubitemid 41464754)
19. Skolnick P, Popik P, Trullas R (2009). Glutamate-based antidepressants : 20 years on. Trends in Pharmacological Sciences 30, 563-569.
20. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, et al. (2004). Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 7, 1-8. (Pubitemid 38523801)
21. Thase ME, Haight BR, Richard N, Rockett CB, et al. (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors : A meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 66, 974-981. (Pubitemid 41191788)
22. Tuominen HJ, Tuominen J, Wahlbeck K (2006). Glutamatergic drugs for schizophrenia. Cochrane Database System Review 2, CD003730.
23. van Berckel BN, Lipsch C, Gispen-de Wied C, Wynne HJ, et al. (1998). The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berlin) 138, 190-197. (Pubitemid 28330837)
24. van Berckel BN, Lipsch C, Timp S, Gispen-de Wied C, et al. (1997). Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 16, 317-324. (Pubitemid 27215599)
25. Zarate CA, Manji HK (2008). The promising role of the glutamate system in mood disorders. In : Heresco-Levy U, Javitt DC (Eds.), Glutamate in Neuropsychiatric Disorders (pp. 213-251). Kerala, India : Research Signpost.